公开(公告)号：EP2734213A4

公开(公告)日：2014-12-10

申请号：EP12814292

申请日：2012-07-18

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： TURECEK PETER ,  VEJDA SUSANNE

IPC: A61K31/737 ,  A61K9/08 ,  A61K9/10 ,  A61K31/715 ,  A61K31/726 ,  A61K38/17 ,  A61P1/00

CPC classification number: A61K38/4846 ,  A61K38/4853 ,  A61K45/06 ,  A61K47/12 ,  A61K47/28 ,  A61K47/36 ,  A61K47/42 ,  A61K2300/00

Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

公开(公告)号：EP2968400A4

公开(公告)日：2016-08-10

申请号：EP14774362

申请日：2014-01-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： TURECEK PETER ,  VEJDA SUSANNE

IPC: A61K31/727 ,  A61P1/00 ,  A61P1/04

CPC classification number: A61K31/727 ,  A61K31/722 ,  A61K38/4873 ,  A61K45/06 ,  A61K47/12 ,  A61K47/28 ,  A61K47/36 ,  A61K47/46 ,  A61K2300/00

Abstract: Aspects of the invention include methods for treating or preventing a thromboembolic disease in a subject. In practicing methods according to certain embodiments, an amount of a low molecular weight heparin (LMWH) and a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers is orally administered to a subject in a manner sufficient to treat the thromboembolic disease in the subject. Compositions and kits for practicing methods of the invention are also described.

公开(公告)号：WO2013012954A3

公开(公告)日：2013-03-21

申请号：PCT/US2012047248

申请日：2012-07-18

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  TURECEK PETER ,  VEJDA SUSANNE

Inventor： TURECEK PETER ,  VEJDA SUSANNE

IPC: A61K31/737 ,  A61K9/08 ,  A61K9/10 ,  A61K31/715 ,  A61K31/726 ,  A61K38/17 ,  A61P1/00

CPC classification number: A61K38/4846 ,  A61K38/4853 ,  A61K45/06 ,  A61K47/12 ,  A61K47/28 ,  A61K47/36 ,  A61K47/42 ,  A61K2300/00

Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

Abstract translation: 本发明的各方面包括用于增强受试者的凝血的方法。 在根据某些实施方案的实践方法中，一定量的非抗凝血硫酸化多糖（NASP）与胃肠上皮屏障渗透促进剂的组合以足以增强受试者中凝血的方式口服给予受试者。 还描述了用于实施本发明方法的组合物和试剂盒。

公开(公告)号：WO2011017414A3

公开(公告)日：2011-03-31

申请号：PCT/US2010044381

申请日：2010-08-04

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  TURECEK PETER ,  AHMAD RAFFI UDIN ,  GRITSCH HERBERT ,  MUCHITSCH EVA-MARIA ,  SCHWARZ HANS-PETER

Inventor： TURECEK PETER ,  AHMAD RAFFI UDIN ,  GRITSCH HERBERT ,  MUCHITSCH EVA-MARIA ,  SCHWARZ HANS-PETER

IPC: C12N15/85 ,  A01K67/027

CPC classification number: C12N15/8509 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03

Abstract: The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.

Abstract translation: 本发明通常涉及血友病A的转基因非人动物模型，其中转基因动物缺乏内源性因子VIII和内源性血管性血友病因子，以及治疗遗传性或获得性血友病A或血管性血友病（VWD）的方法 ）通过外源人VWF的施用。

公开(公告)号：WO2010048184A2

公开(公告)日：2010-04-29

申请号：PCT/US2009061327

申请日：2009-10-20

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  NEKTAR THERAPEUTICS ,  VARADI KATALIN ,  SCHRENK GERALD ,  ROTTENSTEINER HANSPETER ,  TURECEK PETER ,  WEBER ALFRED ,  ANDERLE HEINZ ,  CULBERTSON SEAN M ,  FANG ZHIHAO ,  ZAPPE HAROLD ,  ZHANG PING ,  BOSSARD MARY J

Inventor： VARADI KATALIN ,  SCHRENK GERALD ,  ROTTENSTEINER HANSPETER ,  TURECEK PETER ,  WEBER ALFRED ,  ANDERLE HEINZ ,  CULBERTSON SEAN M ,  FANG ZHIHAO ,  ZAPPE HAROLD ,  ZHANG PING ,  BOSSARD MARY J

IPC: G01N33/542 ,  G01N33/58 ,  G01N33/68 ,  G01N33/86

CPC classification number: G01N33/68 ,  G01N33/542 ,  G01N33/582 ,  G01N33/86 ,  G01N2333/76

Abstract: The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water- soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.

Abstract translation: 本发明涉及从用可逆连接的水溶性聚合物改性的蛋白质强制释放水溶性聚合物如聚乙二醇（PEG）和聚唾液酸（PSA）的体外测定系统的开发。 本发明包括分析水溶性聚合物的释放并测量重新获得的蛋白质活性的方法。 本发明还包括适用于用可释放水溶性聚合物（包括聚合物如PEG和PSA）改性的蛋白质的质量控制的方法。

公开(公告)号：WO2008141824A3

公开(公告)日：2009-03-12

申请号：PCT/EP2008004090

申请日：2008-05-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  MATTHIESSEN PETER ,  ROMEDER-FINGER STEFAN ,  TURECEK PETER ,  SCHWARZ HANS-PETER

Inventor： MATTHIESSEN PETER ,  ROMEDER-FINGER STEFAN ,  TURECEK PETER ,  SCHWARZ HANS-PETER

IPC: C12N9/64 ,  A61K38/48 ,  C07K1/18 ,  C12N15/57

CPC classification number: C12N9/6454 ,  B01D15/363 ,  C12Y304/21075

Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50 -fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.

Abstract translation: 重组截短的人弗林蛋白在CHO细胞中表达，并通过超滤和渗滤浓缩约50倍。 浓缩物通过Capto-MMC柱色谱纯化，得到30-50倍的纯化因子和至少60％的产率。 在Capto-MMC色谱上获得的至少20％的纯制剂已经具有允许原VWF的柱上成熟的纯化程度。 然后进行额外的精氨酸琼脂糖层析纯化。 用于纯化截短的人弗林蛋白酶的这种两柱方法产生几乎纯的弗林蛋白酶制剂，其具有约290,000U弗林蛋白/ mg蛋白质的比活性，约50％的产率。

公开(公告)号：WO2011012850A3

公开(公告)日：2011-04-14

申请号：PCT/GB2010001422

申请日：2010-07-26

Applicant: LIPOXEN TECHNOLOGIES LTD ,  JAIN SANJAY ,  GREGORIADIS GREGORY ,  DWIVEDI ARCHANA ,  NATH SRIJIT ,  SIEKMANN JUERGEN ,  HAIDER STEFAN ,  ROTTENSTEINER HANSPETER ,  TURECEK PETER ,  BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： JAIN SANJAY ,  GREGORIADIS GREGORY ,  DWIVEDI ARCHANA ,  NATH SRIJIT ,  SIEKMANN JUERGEN ,  HAIDER STEFAN ,  ROTTENSTEINER HANSPETER ,  TURECEK PETER

IPC: A61K47/48

CPC classification number: A61K47/6455 ,  A61K47/4823 ,  A61K47/60 ,  A61K47/61 ,  A61K47/65

Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.

Abstract translation: 水溶性聚合物，特别是聚唾液酸（PSA）或改性PSA（mPSA），通过使氧化碳水化合物部分与血液凝固蛋白以外的糖蛋白的氧化碳水化合物部分或神经节苷脂或药物递送系统偶联 与水溶性聚合物接触，其中所述水溶性聚合物含有氨氧基，并且在氧化碳水化合物部分和水溶性聚合物上的氨氧基之间形成肟键，或者其中所述水溶性聚合物含有酰肼基，腙键为 在氧化碳水化合物部分和水溶性聚合物上的酰肼基团之间形成。 因此获得氨氧基或酰肼 - 水溶性聚合物如PSA和mPSA的偶联物，其中PSA或mPSA通过碳水化合物部分连接。

公开(公告)号：WO2010062604A3

公开(公告)日：2010-07-22

申请号：PCT/US2009062228

申请日：2009-10-27

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  SCHWARZ HANS-PETER ,  MUCHITSCH EVA-MARIA ,  TURECEK PETER

Inventor： SCHWARZ HANS-PETER ,  MUCHITSCH EVA-MARIA ,  TURECEK PETER

IPC: C12N15/85 ,  A01K67/027 ,  A61K49/00

CPC classification number: A61K49/0008 ,  A01K67/027 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  A01K2267/0325 ,  A01K2267/0381 ,  C12N15/8509

Abstract: The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.

Abstract translation: 本发明涉及用于测试治疗凝血障碍的各种药剂的动物模型的开发。 更具体地说，本发明涉及在各种小鼠品系中使用冯 - 维勒布兰德因子（VWF）的超大分子量多聚体来诱导血栓形成血小板减少性紫癜（TTP）样症状，用于发展TTP小鼠模型。 本发明还提供了产生这种动物疾病模型的方法和用于鉴定在治疗TTP中有效的生物活性化合物的筛选方法。

公开(公告)号：WO2010020423A3

公开(公告)日：2010-05-27

申请号：PCT/EP2009006082

申请日：2009-08-21

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT ,  DOCKAL MICHAEL ,  SCHEIFLINGER FRIEDRICH ,  TURECEK PETER

Inventor： DOCKAL MICHAEL ,  SCHEIFLINGER FRIEDRICH ,  TURECEK PETER

IPC: A61K31/737 ,  A61K31/727 ,  A61P7/04

CPC classification number: A61K31/737 ,  A61K31/727 ,  A61K38/36 ,  A61K38/366 ,  A61K38/37 ,  A61K38/4846 ,  A61K38/4853 ,  A61K45/06 ,  G01N33/86 ,  A61K2300/00

Abstract: A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor Xl; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor Xl-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

Abstract translation: 在需要增强血液凝固的受试者中增强因子XI依赖性血液凝固的方法，包括向受试者施用治疗有效量的包含非抗凝血剂硫酸化多糖（NASP）的组合物。 一种在需要增强血液凝固的受试者中增强因子XI依赖性血液凝固的方法，包括：（i）选择对于因子XI不缺乏的受试者; 和（ii）将治疗有效量的包含非抗凝血剂硫酸化多糖（NASP）的组合物给予所述受试者，其中所述NASP以因子XI依赖性方式增强凝血。 一种鉴定能够根据FXI增强血液凝固的非抗凝血硫酸化多糖（NASP）的方法，所述方法包括：a）将包含活化能力FXI的血液或血浆样品与包含硫酸化多糖的组合物混合并测量 血液或血浆样品的凝血或凝血酶生成参数; b）将缺乏活化能力的FXI的相应血液或血浆样品与包含硫酸化多糖的组合物组合并测量血液或血浆样品的凝固或凝血酶生成参数; 和c）将在步骤（a）和（b）中确定的血液或血浆样品的凝血或凝血酶生成参数彼此比较，其中血样的凝固时间减少或峰值凝血酶增加或降低 在包含活化能力FXI的血浆样品的峰值时间与血液样品或峰值凝血酶的凝固时间相比较或缺乏活化能力的血浆样品的峰值时间FXI表明NASP能够依赖于 FXI。

公开(公告)号：WO2006021314A2

公开(公告)日：2006-03-02

申请号：PCT/EP2005008467

申请日：2005-08-04

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  ANDERLE HEINZ ,  MATTHIESSEN PETER ,  SCHWARZ HANS-PETER ,  TURECEK PETER ,  KREIL THOMAS ,  BOGGS DANIEL R

Inventor： ANDERLE HEINZ ,  MATTHIESSEN PETER ,  SCHWARZ HANS-PETER ,  TURECEK PETER ,  KREIL THOMAS ,  BOGGS DANIEL R

IPC: A61L2/10 ,  A61L2/28 ,  C02F1/32 ,  G01J1/00 ,  G01N23/00 ,  G01T1/00

CPC classification number: A61L2/10 ,  A23L3/26 ,  A23L3/28 ,  A61L2/0011 ,  A61L2/28 ,  G01N21/33 ,  H05B3/0052

Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivete microorganisms present in a biological fluid, preferably a non-trannsparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.